A detailed history of Barclays PLC transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Barclays PLC holds 273,019 shares of STRO stock, worth $513,275. This represents 0.0% of its overall portfolio holdings.

Number of Shares
273,019
Previous 273,019 -0.0%
Holding current value
$513,275
Previous $944,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$2.88 - $5.01 $624,260 - $1.09 Million
216,757 Added 385.26%
273,019 $944,000
Q2 2024

Aug 14, 2024

SELL
$2.92 - $5.33 $68,549 - $125,127
-23,476 Reduced 29.44%
56,262 $164,000
Q1 2024

May 15, 2024

SELL
$3.27 - $5.65 $171,089 - $295,613
-52,321 Reduced 39.62%
79,738 $450,000
Q4 2023

Feb 15, 2024

BUY
$2.07 - $4.54 $143,823 - $315,439
69,480 Added 111.03%
132,059 $566,000
Q3 2023

Nov 07, 2023

BUY
$3.29 - $4.9 $59,525 - $88,655
18,093 Added 40.67%
62,579 $217,000
Q2 2023

Aug 03, 2023

SELL
$4.25 - $5.88 $325,796 - $450,749
-76,658 Reduced 63.28%
44,486 $207,000
Q1 2023

May 04, 2023

BUY
$4.48 - $8.45 $175,817 - $331,620
39,245 Added 47.92%
121,144 $559,000
Q4 2022

Feb 13, 2023

BUY
$5.41 - $8.08 $332,552 - $496,677
61,470 Added 300.9%
81,899 $661,000
Q3 2022

Nov 03, 2022

SELL
$5.17 - $7.11 $17,624 - $24,237
-3,409 Reduced 14.3%
20,429 $114,000
Q2 2022

Aug 12, 2022

SELL
$3.41 - $8.95 $101,457 - $266,289
-29,753 Reduced 55.52%
23,838 $125,000
Q1 2022

May 16, 2022

SELL
$7.78 - $15.31 $2.34 Million - $4.61 Million
-300,796 Reduced 84.88%
53,591 $441,000
Q4 2021

Feb 14, 2022

BUY
$14.25 - $23.53 $338,622 - $559,143
23,763 Added 7.19%
354,387 $5.27 Million
Q3 2021

Nov 09, 2021

BUY
$16.88 - $22.38 $1.55 Million - $2.05 Million
91,630 Added 38.34%
330,624 $6.25 Million
Q2 2021

Aug 13, 2021

SELL
$18.03 - $23.82 $380,955 - $503,292
-21,129 Reduced 8.12%
238,994 $4.44 Million
Q1 2021

May 13, 2021

BUY
$20.29 - $27.54 $608,781 - $826,310
30,004 Added 13.04%
260,123 $5.92 Million
Q4 2020

Feb 11, 2021

SELL
$10.16 - $23.98 $91,500 - $215,963
-9,006 Reduced 3.77%
230,119 $5 Million
Q3 2020

Nov 12, 2020

BUY
$7.44 - $13.15 $13,139 - $23,222
1,766 Added 0.74%
239,125 $2.4 Million
Q2 2020

Aug 12, 2020

BUY
$7.24 - $11.05 $53,706 - $81,968
7,418 Added 3.23%
237,359 $1.84 Million
Q1 2020

May 13, 2020

BUY
$6.19 - $12.16 $1.31 Million - $2.57 Million
211,642 Added 1156.58%
229,941 $2.35 Million
Q4 2019

Feb 10, 2020

BUY
$8.15 - $11.39 $45,371 - $63,408
5,567 Added 43.72%
18,299 $202,000
Q3 2019

Nov 14, 2019

BUY
$7.91 - $11.76 $23,777 - $35,350
3,006 Added 30.91%
12,732 $116,000
Q2 2019

Aug 14, 2019

BUY
$9.69 - $12.23 $76,744 - $96,861
7,920 Added 438.54%
9,726 $111,000
Q1 2019

May 15, 2019

BUY
$8.8 - $11.87 $7,101 - $9,579
807 Added 80.78%
1,806 $21,000
Q4 2018

Feb 14, 2019

BUY
$8.69 - $14.85 $8,681 - $14,835
999 New
999 $9,000

Others Institutions Holding STRO

About SUTRO BIOPHARMA, INC.


  • Ticker STRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,161,500
  • Market Cap $98.1M
  • Description
  • Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...
More about STRO
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.